Microbiome contract development and manufacturing organization (CDMO) List Labs has partnered with the global clinical stage biotechnology company, Genome & Company. Republic of South Korea based Genome & Company has entered into agreements subject to regulatory approval to acquire controlling interest in U.S. based List Biological Laboratories, Inc. (List Labs). The resulting partnership creates the first global live biotherapeutic drug development company with integrated contract development and manufacturing capabilities.
 
The partnership will allow List Labs to attain its strategic vision to expand and build additional capacity and accelerate the realization of an end-to-end solution for all phases of clinical trial material and commercial production. List Labs will maintain independent operational control of all client activities, ensuring the confidentiality of contract client’s proprietary information. This will allow List Labs to generate revenue by continuing to provide CDMO services to the open market. In addition, List Labs will continue to serve its global customer base with high-quality bacterial products, including toxins and cGMP LPS, a legacy established in 1978.
 
The synergistic relationship with Genome & Company will leverage our shared drive to become the leading global CDMO specialized in the microbiome.
 
In the past decade, leveraging bacterial strain experience and expertise, List Labs has developed cGMP manufacturing expertise and compliance standards that have provided an impressive array of global organizations with phase 1 and 2 clinical trial material, pioneering the development of Live Biotherapeutic Products for a wide range of indications.
 
“We are thrilled to strengthen List Lab’s capabilities to serve our microbiome CDMO customers,” said Stacy Burns-Guydish, president and CEO, List Labs. “The synergistic relationship with Genome & Company will leverage our shared drive to become the leading global CDMO specialized in the microbiome. The resulting organization will offer the best drug development and manufacturing opportunity for early and late-stage clients seeking an integrated end to end solution for their drug development pipeline. Our reputation for quality, expertise, and experience, is well known in the industry. Expanding our capacity and global presence is the next logical step.”
 
Jisoo Pae, CEO of Genome & Company, said, “Our desire is to pioneer and pave new paths for the microbiome industry. The creation of this unique and differentiated business model provides two successful, cutting-edge organizations with the additional resources necessary to break new ground.”  
 
As the live biotherapeutic product market continues to grow, the demand for high quality development and manufacturing options in the microbiome space also increases exponentially. In 2021, approximately 204 microbiome projects are under development. Market forecast predictions indicate an increase in total market value from $56.3 million in 2018 to $9.4 billion in 2024, representing an increase of 167 times.